6533b821fe1ef96bd127b099
RESEARCH PRODUCT
Hypothesis: can N-acetylcysteine be beneficial in Parkinson's disease?
M. MartínezNatividad Martı́nezMaría Luisa FerrándizAna Isabel Hernándezsubject
Parkinson's diseaseAntioxidantmedicine.medical_treatmentModels NeurologicalSubstantia nigraOxidative phosphorylationPharmacologyBiologyMitochondrionNeuroprotectionGeneral Biochemistry Genetics and Molecular BiologyOxidative PhosphorylationAcetylcysteineAdenosine TriphosphatemedicineNAD(P)H Dehydrogenase (Quinone)HumansGeneral Pharmacology Toxicology and Pharmaceuticschemistry.chemical_classificationReactive oxygen speciesParkinson DiseaseGeneral Medicinemedicine.diseaseCorpus StriatumAcetylcysteineMitochondriaSubstantia NigraNeuroprotective AgentschemistryReactive Oxygen SpeciesNeurosciencemedicine.drugdescription
Based on the finding of decreased mitochondrial complex I activity in the substantia nigra of patients with Parkinson's disease, we propose that the consequent reduction of ATP synthesis and increased generation of reactive oxygen species may be a possible cause of nigrostriatal cell death. Since sulfhydryl groups are essential in oxidative phosphorylation, thiolic antioxidants may contribute to the preservation of these proteins against oxidative damage. In the present paper, we hypothesize that treatment with a sulfur-containing antioxidant such as N-acetylcysteine may provide a new neuroprotective therapeutic strategy for Parkinson's disease.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1999-05-05 | Life sciences |